Sangamo Therapeutics (SGMOQ) Other financing activities (2013 - 2025)

Sangamo Therapeutics has reported Other financing activities for 11 years, with the latest figure at $15.0 million in Q4 2025.

• On a quarterly basis, Other financing activities rose 114.46% year-over-year to $15.0 million in Q4 2025; TTM through Dec 2025 was $52.2 million, a 631.7% increase from a year earlier, with the FY2025 full-year figure at $52.2 million, up 631.7% from the prior year.
• Other financing activities was $15.0 million for Q4 2025 at Sangamo Therapeutics, down from $19.6 million in the prior quarter.
• The five-year high for Other financing activities was $22.5 million in Q1 2024, with the low at -$22.4 million in Q2 2024.
• Average Other financing activities over 5 years is $4.4 million, with a median of $1.1 million recorded in 2021.
• The sharpest annual moves came in 2023 and 2024: Other financing activities surged 4393.75% in 2023, then slumped 3212.38% in 2024.
• Over 5 years, Other financing activities stood at $1.1 million in 2021, then plunged by 96.81% to $34000.0 in 2022, then jumped by 535.29% to $216000.0 in 2023, then soared by 3134.26% to $7.0 million in 2024, then soared by 114.46% to $15.0 million in 2025.
• The last three Other financing activities figures came in at $15.0 million (Q4 2025), $19.6 million (Q3 2025), and $17.6 million (Q2 2025), per Business Quant data.